6:01 PM
 | 
Dec 14, 2011
 |  BC Extra  |  Clinical News

LibiGel fails to excite in Phase III trials

BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) said LibiGel Transdermal testosterone gel missed the co-primary endpoints vs. placebo in the Phase III BLOOM-1 and BLOOM-2 trials to treat hypoactive sexual desire disorder in menopausal women. LibiGel did not significantly increase the total number...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >